{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:37:28Z","timestamp":1793191048875,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40268-016-0131-2","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T16:32:00Z","timestamp":1459355520000},"page":"217-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Dual Bronchodilator Therapy with Umeclidinium\/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial"],"prefix":"10.1007","volume":"16","author":[{"given":"Chris","family":"Kalberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Galkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Newlands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Fahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,30]]},"reference":[{"key":"131_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, 2015. Available at http:\/\/www.goldcopd.com . Accessed on 03 Dec 2015."},{"key":"131_CR2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4104\/pcrj.2010.00059","volume":"20","author":"MT Dransfield","year":"2011","unstructured":"Dransfield MT, Bailey W, Crater G, Emmett A, O\u2019Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2011;20:46\u201353.","journal-title":"Prim Care Respir J."},{"key":"131_CR3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40265-014-0326-1","volume":"75","author":"HA Blair","year":"2015","unstructured":"Blair HA, Deeks ED. Umeclidinium\/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs. 2015;75:61\u201374.","journal-title":"Drugs."},{"key":"131_CR4","unstructured":"GSK. Anoro\u2122 ELLIPTA\u2122 prescribing information, 2014. Available at https:\/\/www.gsksource.com\/gskprm\/htdocs\/documents\/ANORO-ELLIPTA-PI-MG.PDF . Accessed on 03 Dec 2015."},{"key":"131_CR5","unstructured":"GSK. Anoro\u2122 ELLIPTA\u2122 summary of product characteristics, 2014. Available at http:\/\/www.medicines.org.uk\/emc\/medicine\/28949#INDICATIONS . Accessed on 03 Dec 2015."},{"key":"131_CR6","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","volume":"107","author":"JF Donohue","year":"2013","unstructured":"Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25\u00a0mcg in COPD. Respir Med. 2013;107:1538\u201346.","journal-title":"Respir Med."},{"key":"131_CR7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","volume":"2","author":"M Decramer","year":"2014","unstructured":"Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24\u00a0weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472\u201386.","journal-title":"Lancet Respir Med."},{"key":"131_CR8","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.rmed.2014.10.002","volume":"108","author":"MR Maleki-Yazdi","year":"2014","unstructured":"Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium\/vilanterol 62.5\/25\u00a0mcg and tiotropium 18\u00a0mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108:1752\u201360.","journal-title":"Respir Med."},{"key":"131_CR9","unstructured":"Boehringer Ingelheim. Spiriva\u00ae HandiHaler\u00ae prescribing information, 2014. Available at http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Spiriva\/Spiriva.pdf . Accessed on 03 Dec 2015."},{"key":"131_CR10","unstructured":"Boehringer Ingelheim. Spiriva\u00ae HandiHaler\u00ae summary of product characteristics, 2015. Available at https:\/\/www.medicines.org.uk\/emc\/medicine\/10039 . Accessed on 03 Dec 2015."},{"key":"131_CR11","unstructured":"Novartis. Arcapta\u2122 Neohaler\u2122 prescribing information, 2011. Available at https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/arcapta.pdf . Accessed on 03 Dec 2015."},{"key":"131_CR12","unstructured":"Novartis. Onbrez\u00ae Breezhaler\u00ae summary of product characteristics, 2014. Available at https:\/\/www.medicines.org.uk\/EMC\/medicine\/23260\/SPC\/Onbrez+Breezhaler+150+and+300+microgram+inhalation+powder,+hard+capsules\/ . Accessed on 03 Dec 2015."},{"key":"131_CR13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543\u201354.","journal-title":"N Engl J Med."},{"key":"131_CR14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","volume":"182","author":"JF Donohue","year":"2010","unstructured":"Donohue JF, Fogarty C, L\u00f6tvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:155\u201362.","journal-title":"Am J Respir Crit Care Med."},{"key":"131_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2466-10-11","volume":"10","author":"G Feldman","year":"2010","unstructured":"Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150\u00a0\u03bcg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.","journal-title":"BMC Pulm Med."},{"key":"131_CR16","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH]. ICH harmonised tripartite guideline: guideline for good clinical practice E6(1), 1996 (cited 2013 May). Available at http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf . Accessed on 03 Dec 2015."},{"key":"131_CR17","unstructured":"World Medical Association [WMA]. WMA Declaration of Helsinki\u2014ethical principles for medical research involving human subjects, 2013 [cited 2013 May]. Available at http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html . Accessed on 03 Dec 2015."},{"key":"131_CR18","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","volume":"23","author":"BR Celli","year":"2004","unstructured":"Celli BR. MacNee W; ATS\/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper. Eur Respir J. 2004;23:932\u201346.","journal-title":"Eur Respir J."},{"key":"131_CR19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/COPD-200050666","volume":"2","author":"DA Mahler","year":"2005","unstructured":"Mahler DA, Witek TJ Jr. The MCID of the Transition Dyspnea Index is a total score of one unit. COPD. 2005;2:99\u2013103.","journal-title":"COPD."},{"key":"131_CR20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","volume":"2","author":"PW Jones","year":"2005","unstructured":"Jones PW. St. George\u2019s Respiratory Questionnaire: MCID. COPD. 2005;2:75\u20139.","journal-title":"COPD."},{"key":"131_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/CVM-1-1-019","volume":"1","author":"SM Snapinn","year":"2000","unstructured":"Snapinn SM. Noninferiority trials. Curr Control Trials Cardiovasc Med. 2000;1:19\u201321.","journal-title":"Curr Control Trials Cardiovasc Med."},{"key":"131_CR22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2466-14-4","volume":"14","author":"KR Chapman","year":"2014","unstructured":"Chapman KR, Beeh KM, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4.","journal-title":"BMC Pulm Med."},{"key":"131_CR23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1465-9921-11-135","volume":"11","author":"C Vogelmeier","year":"2010","unstructured":"Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res. 2010;11:135.","journal-title":"Respir Res."},{"key":"131_CR24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/bjc.1993.402","volume":"68","author":"JA Lewis","year":"1993","unstructured":"Lewis JA, Machin D. Intention to treat\u2014who should use ITT? Br J Cancer. 1993;68:647\u201350.","journal-title":"Br J Cancer."},{"key":"131_CR25","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH]. ICH harmonised tripartite guideline: statistical principles for clinical trials E9, 1998. Available at http:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/statistical-principles-for-clinical-trials.html . Accessed on 03 Dec 2015."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0131-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-016-0131-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0131-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:15:55Z","timestamp":1553613355000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-016-0131-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,30]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["131"],"URL":"https:\/\/doi.org\/10.1007\/s40268-016-0131-2","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,30]]}}}